Medical News

RSS

Update on new clinical developments and other initiatives related to Ceplene

EpiCept Corporation today provided an update on new clinical developments and other initiatives related to Ceplene® (histamine dihydrochloride), the Company’s therapy approved in the European Union for the remission maintenance and prevention of relapse of patients with acute myeloid leukemia (AML) in first remission.

15 Dec 2009

Tel Aviv University researchers unravel the mysteries of DNA packaging

The RNA "spools" that make up DNA in our genes need careful editing, too. Genes are composed of meaningful sequences, called exons, separated by meaningless junk sections called introns.

15 Dec 2009

Study reveals wide variations in health and sustainability across English populations

A new study by experts at the University of the West of England (UWE, Bristol) has revealed wide and significant variations in the health and sustainability of populations across England.

15 Dec 2009

HealthPort's RACPro now holds the distinction of being RACTrac Compatible

HealthPort®, Inc., a top 25-company in the healthcare information technology industry, today announced its recovery audit contractor (RAC) management tool, HealthPort RACPro, now holds the distinction, through the American Hospital Association (AHA), of being RACTrac Compatible.

15 Dec 2009

Geron’s request for declaration of interference regarding Novocell' U.S. Patent No. 7,510,876 granted

Geron Corporation today announced that the U.S. Patent and Trademark Office, Board of Patent Appeals and Interferences, has granted Geron’s request to declare an interference between a patent application owned by Geron and U.S. Patent No. 7,510,876 (the ‘876 patent) owned by Novocell, Inc.

15 Dec 2009

Study compares status of health care systems in U.S. and UK

The well-worn notion that patients in the United States have unfettered access to the most expensive cancer drugs while the United Kingdom's nationalized health care system regularly denies access to some high-cost treatments needs rethinking, a team of bioethicists and health policy experts says in a report out today.

15 Dec 2009

Hospitals to find acceptable alternatives to STERIS System 1 sterile processing system

In response to an FDA notice issued on December 3, 2009, in which the Agency recommended that healthcare facilities discontinue use of the STERIS System 1® (SS1) sterile processing system, hospitals throughout the U.S. are faced with the task of finding acceptable alternatives to that product.

15 Dec 2009

ProChon Biotech announces expansion of BioCart Cartilage Regeneration System study

ProChon Biotech, Ltd., an innovator of tissue regenerative technologies that are being developed to relieve pain and restore the mobility and quality of life for sufferers of articular cartilage injuries, today announced a significant expansion of its clinical study of the BioCart™ Cartilage Regeneration System.

15 Dec 2009

Study may pave way for effective drug development for childhood leukemia

A new study could point the way to the development of better drugs to fight a deadly form of childhood leukemia called mixed-lineage leukemia (MLL).

15 Dec 2009

Modifications to Phase II study AD201 and open label extension study AD251 for ELND005 notified

Elan Corporation, plc and Transition Therapeutics, Inc. today notified clinical investigators of modifications to the Phase II study AD201 and open label extension study AD251 for ELND005, a compound being developed for the potential treatment of Alzheimer’s disease.

15 Dec 2009

New highly sensitive CFSE T cell proliferation assays launched by ProImmune

ProImmune Ltd, a leader in epitope discovery, immunogenicity and immune monitoring products and services, has launched CFSE T cell proliferation assays for immunogenicity risk assessment. The new highly sensitive assays form part of ProImmune’s REVEAL Immunogenicity System, a suite of tools used in the design and selection of biological drug leads at the preclinical stage.

15 Dec 2009

Protein interaction study may provide vital clues to limb regeneration

The most comprehensive study to date of the proteins in a species of salamander that can regrow appendages may provide important clues to how similar regeneration could be induced in humans.

15 Dec 2009

Anthem Blue Cross to receive Tri-County Commercial contract renewal award

Anthem Blue Cross announced today that the California Department of Health Care Services intends to award Anthem the Tri-County Commercial contract renewal to provide Medi-Cal benefits to residents in the Fresno, Kings and Madera Counties.

15 Dec 2009

Reducing TV time may help prevent obesity in adults

Adults who used an electronic lock-out system to reduce their television time by half did not change their calorie intake but did expend more energy over a three-week period, according to a report in the December 14/28 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

15 Dec 2009

The United States Senate passes funding for teen pregnancy prevention program

The United States Senate yesterday passed a package of spending bills for FY 2010, which included a historic new investment in efforts to prevent teen pregnancy.

15 Dec 2009

Utah may be forced to raise Medicaid payments for dentists; mandatory student insurance would benefit Florida

News outlets report on Medicaid dental payments in Utah, student insurance in Florida, Illinois budget woes and emergency rooms in Massachusetts.

15 Dec 2009

Nanoparticle could allow diagnosis and treatment in one visit

Researchers at Rice University and Baylor College of Medicine (BCM) have created a single nanoparticle that can be tracked in real time with MRI as it homes in on cancer cells, tags them with a fluorescent dye and kills them with heat.

15 Dec 2009

Spending on health care eventually leads to economic growth increase

As the national discussion of health care focuses on costs, a new study from North Carolina State University shows that it might be more accurate to think of health care spending as an investment that can spur economic growth.

15 Dec 2009

Phase III clinical trial evaluating darusentan misses its co-primary efficacy endpoints

Gilead Sciences, Inc. today announced that DAR-312 (DORADO-AC), a Phase III clinical trial evaluating darusentan, the company’s endothelin receptor antagonist (ERA) for the treatment of resistant hypertension, did not achieve its co-primary efficacy endpoints of change from baseline to week 14 in trough sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) compared to placebo.

15 Dec 2009

Mylan to be added to NASDAQ-100 Index

Mylan Inc. today announced that the company will be added to the NASDAQ-100 Index Dec. 21. Mylan's common shares will also be included in NASDAQ's PowerShares QQQ.

15 Dec 2009